文献速递慢性静脉疾病

病理性大隐静脉及穿通静脉经皮治疗方式结局的系统综述

A systematic review of the outcomes of percutaneous treatment modalities for pathologic saphenous and perforating veins.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2022-03-30

本系统综述纳入35项研究,评估经皮腔内激光消融、射频消融及超声引导硬化剂治疗病理性穿通静脉(伴或不伴大/小隐静脉)的结局。各技术围术期安全性良好,EVLA与RFA技术成功率和12个月闭塞率优于USGS,但证据级别有限,需进一步研究验证。

要点

  • EVLA组即刻手术成功率为95%,RFA组为91%,USGS组为58%至70%。
  • 12个月随访时EVLA、RFA和USGS组闭塞率分别为89%、77%和83%。
  • EVLA与RFA组12个月溃疡愈合合并估计值相似,但未进行直接比较。

核心结论

  • 经皮技术(EVLA、RFA、USGS)治疗穿通静脉安全且技术成功率高。
  • EVLA和RFA显示出最有利的结局。
  • 需要额外研究来验证这些基于有限证据水平的结果,以更好地确定下肢病理性穿通静脉的最佳治疗方法。

研究设计与样本

  • 遵循PRISMA指南的系统综述,纳入截至2020年3月报告的35项研究。
  • 15项研究(n=1677)报告EVLA伴或不伴硬化剂治疗和/或微创静脉切除术。
  • 12项研究(n=1477)探讨RFA消融伴或不伴硬化剂治疗的结局。
  • 8项研究(n=331)探讨单独USGS。

主要发现

  • 所有技术围术期不良事件方面安全,每组仅发生少数并发症。
  • 即刻手术成功(30天内):EVLA组95%,RFA组91%,USGS组58%至70%。
  • 12个月随访闭塞率:EVLA组89%,RFA组77%,USGS组83%。
  • EVLA与RFA组12个月溃疡愈合合并估计值相似,但未进行直接比较。

局限性

  • 结果基于有限的证据水平。
  • 需要额外研究来验证这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Minimally invasive techniques have been increasingly used to treat pathologic perforator veins (PVs). The goal of the present study was to summarize the current literature and determine the outcomes of treating PVs with or without the great saphenous vein/small saphenous vein using endovenous laser ablation (EVLA), radiofrequency ablation (RFA), and ultrasound-guided sclerotherapy (USGS). METHODS: A systematic review of the literature on the percutaneous treatment of PVs (35 studies) was conducted in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Studies reported up to March 2020 were included. The incidence of several end points at different follow-up periods were calculated according to the availability of data within 3 to 12 months after the index procedure. RESULTS: Of the 35 studies, 15 (n = 1677) had reported on EVLA with or without sclerotherapy and/or microphlebectomy, 12 (n = 1477) had investigated the outcomes of RFA ablation with/without sclerotherapy, and 8 (n = 331) had investigated USGS alone. All techniques were safe in terms of periprocedural adverse events, with only a few complications occurring in each group. Immediate procedural success (within 30 days) was 95% in the EVLA group, 91% in the RFS group, and 58% to 70% in the USGS group. At 12 months of follow-up, the occlusion rates were 89%, 77%, and 83% in the EVLA, RFA, and USGS groups, respectively. The 12-month pooled estimate of ulcer healing between the EVLA and RFA groups was similar, although no direct comparisons were performed. CONCLUSIONS: Treatment of PVs with percutaneous techniques, such as EVLA, RFA, and USGS, is safe and associated with high technical success. EVLA and RFA exhibited the most favorable outcomes. Additional research is needed to validate these results, which were based on the limited level of evidence available to better determine the most optimal treatment approach for lower limb pathologic PVs.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Giannopoulos S, Rodriguez L, Chau M, et al. A systematic review of the outcomes of percutaneous treatment modalities for pathologic saphenous and perforating veins. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 35364302. doi:10.1016/j.jvsv.2022.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。